Sichuan Haisco Pharmaceutical
Chengdu, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A fully integrated Chinese pharma company developing and commercializing small molecules and biologics across multiple therapeutic areas.
Central Nervous SystemOncologyAutoimmune
Technology Platform
Platforms for novel small molecule derivatives and biologics development, including monoclonal antibodies and long-acting protein therapeutics.
Opportunities
Potential to capitalize on China's national drug reimbursement list (NRDL) inclusions for its innovative products to drive significant revenue growth.
Risk Factors
Exposure to ongoing Chinese healthcare reform and generic drug price erosion, which could pressure profitability.
Competitive Landscape
Competes with numerous other integrated Chinese pharmaceutical companies in the generics and fast-follower innovative drug space.